Zevra Therapeutics Completes Acquisition of Acer Therapeutics

Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, has announced the completion of its acquisition of Acer Therapeutics Inc. (Acer) which marks a significant step forward in executing Zevra’s strategy to become a leader in developing and commercializing treatments for rare diseases and furthers the Company’s commitment to supporting patient communities with limited or no existing therapeutic options. The acquisition of Acer brings multiple rare disease assets and increases Zevra’s revenue potential with the addition of OLPRUVA®, which is indicated for the treatment of certain urea cycle disorders (UCDs), expands Zevra’s clinical portfolio with EDSIVO™, currently in Phase 3 for vascular Ehlers-Danlos syndrome (vEDS).

Read the full article: Zevra Therapeutics Completes Acquisition of Acer Therapeutics //

Source: https://www.globenewswire.com/news-release/2023/11/20/2783148/16626/en/Zevra-Therapeutics-Completes-Acquisition-of-Acer-Therapeutics-in-its-Journey-to-Become-a-Leading-Rare-Disease-Company.html

Leave a Comment

Your email address will not be published.

Scroll to Top